Colorectal cancer (CRC) ranks third among the most frequent malignancies and represents the second most common cause of cancer-related deaths worldwide. By interfering with the DNA replication process of cancer cells, several chemotherapeutic molecules used in CRC therapy induce replication stress (RS). At the cellular level, this stress is managed by the ATR-CHK1 pathway, which activates the replication checkpoint. In recent years, the therapeutic value of targeting this pathway has been demonstrated. Moreover, MSI + (microsatellite instability) tumors frequently harbor a nonsense, heterozygous mutation in the ATR gene. Using isogenic HCT116 clones, we showed that this mutation of ATR sensitizes the cells to several drugs, including SN-38 (topoisomerase I inhibitor) and VE-822 (ATR inhibitor) and exacerbates their synergistic effects. We showed that this mutation bottlenecks the replication checkpoint leading to extensive DNA damage. The combination of VE-822 and SN-38 induces an exhaustion of RPA and a subsequent replication catastrophe. Surviving cells complete replication and accumulate in G2 in a DNA-PK-dependent manner, protecting them from cell death. Together, our results suggest that RPA and DNA-PK represent promising therapeutic targets to optimize the inhibition of the ATR-CHK1 pathway in oncology. Ultimately, ATR frameshift mutations found in patients may also represent important prognostic factors.
Pubmed ID: 35361811 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This monoclonal targets RPA32/RPA2
View all literature mentionsThis monoclonal targets GAPDH antibody [6C5]
View all literature mentionsThis monoclonal targets KAP1
View all literature mentionsThis monoclonal secondary targets IgG1
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal targets IgG (H+L)
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis unknown targets IgG(H+L)
View all literature mentionsThis polyclonal targets mouse IgG
View all literature mentionsThis polyclonal targets KAP1 (phospho S143) antibody
View all literature mentionsThis monoclonal targets CHEK2
View all literature mentionsThis monoclonal targets ATM (D2E2) Rabbit mAb
View all literature mentionsThis unknown targets 53BP1, phospho (Ser1778)
View all literature mentionsThis polyclonal targets beta Tubulin antibody - Loading Control
View all literature mentionsThis unknown targets Phospho-RPA32 (Ser4, Ser8)
View all literature mentionsThis monoclonal targets DNA, single stranded
View all literature mentionsThis monoclonal targets Chek1
View all literature mentionsThis monoclonal targets Chk1, phospho (Ser345)
View all literature mentionsThis polyclonal targets ATR (phospho Thr1989)
View all literature mentionsThis monoclonal targets ATM
View all literature mentionsThis unknown targets DNA-PK
View all literature mentionsThis polyclonal targets Human DNA PKcs (phospho S2056)
View all literature mentionsThis unknown targets Chk2, phospho (Ser19)
View all literature mentionsThis polyclonal targets TRIM28
View all literature mentionsThis monoclonal targets Histone H2A.X, phospho (Ser139)
View all literature mentionsThis polyclonal targets Cleaved Caspase-3 (Asp175)
View all literature mentionsCell line HCT 116 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentions